Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 618 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Serplulimab July 31, 2026 New analysis estimates over 21 million UK adults will be obese... May 18, 2022 Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... January 27, 2025 How I Navigated the Challenges of 2 Colorectal Cancer Diagnoses As... January 6, 2022 Load more HOT NEWS Study Offers Insights on Health Problems among AYA Cancer Survivors Coping With War and Cancer: How to Take Care of Your... Coping With Social Isolation as a Teen With Cancer The award-winning researcher behind next generation sequencing
